MAIA

アフターアワーズ： 1.25 -0.03 -2.34%

MAIA Biotechnology Inc (MAIA)

概要ニュース株価時系列ディスカッション予測

Relative Volume:

ネットキャッシュフロー:

MAIA Biotechnology Inc Stock (MAIA) Company Profile

MAIA Biotechnology Inc

Healthcare (1074)

Biotechnology (599)

312 416 8592

444 West Lake Street, Suite 1700, Chicago

MAIA's Discussions on Twitter

Compare MAIA vs VRTX, REGN, ARGX, RVMD, ALNY

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
MAIA MAIA Biotechnology Inc	1.28	75.39M	0	-24.25M	-19.95M	-0.6796
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

MAIA Biotechnology Inc (MAIA) 最新ニュース

MAIA Biotechnology Inc (MAIA) 財務データ

MAIA Biotechnology Inc (MAIA)

MAIA Biotechnology Inc Stock (MAIA) Company Profile

Compare MAIA vs VRTX, REGN, ARGX, RVMD, ALNY

MAIA Biotechnology Inc (MAIA) 最新ニュース

Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey

MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey

Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Maia Biotechnology Inc (MAIA) Cash Flow - TradingKey

MAIA Biotechnology Edges Lower as Support Level Faces TestVol Target Rebalance - Bölüm Sonu Canavarı

Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA) - The Globe and Mail

Data released by MAIA Biotechnology Inc. show that the combination therapy of its candidate drug Apatganosin with Ximiprilizumab demonstrated an acceptable safety profile in a heavily pre-treated population of patients with advanced solid tumors. - Bitget

Maia Biotechnology Reports Initial Efficacy Data from Phase 2 Thio-101 Part C Expansion Trial in Third-Line Non-Small Cell Lung Cancer - marketscreener.com

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - The Manila Times

MAIA Biotechnology Reports 90.5% Interim Disease Control Rate in Phase 2 THIO-101 Part C for Advanced NSCLC - Quiver Quantitative

MAIA Biotechnology Reports Strong Initial Efficacy Data in - GlobeNewswire

MAIA Biotechnology (MAIA) Faces Selling Pressure as Shares Approach Key SupportIPO Entry Watch - dars.gov.et

MAIA Biotechnology Inc. (MAIA) Rises 3.1% as Shares Approach Key ResistanceVolume Profile - DonanımHaber

Enterprise value to EBITDA forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView

Price to earnings forward of MAIA Biotechnology, Inc. – BOATS:MAIA - TradingView

MAIAMAIA Biotechnology Inc Dividends - Finviz

ETFs Investing in MAIA Biotechnology, Inc. Stocks - TradingView

MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options - Stock Titan

MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44 - Stock Titan

MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant - Stock Titan

MAIA Biotechnology (NASDAQ: MAIA) director granted 27,610 stock options at $1.44 strike - Stock Titan

Director at MAIA Biotechnology (MAIA) receives 32,003 stock options grant - Stock Titan

26,355 stock options granted to MAIA (NASDAQ: MAIA) director Jean-Manasse - Stock Titan

MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline AdvancesRevenue Report - dars.gov.et

MAIA Forecast — Price Target — Prediction for 2027 - TradingView

MAIA Biotechnology, Inc. Actuals & Estimates (AMEX:MAIA) - TradingView

MAIA Biotechnology, Inc. Actuals & Estimates (BOATS:MAIA) - TradingView

Why Is MAIA Biotechnology (NYSE:MAIA) Tracking Higher on Trial News? - Kalkine Media

MAIA finishes THIO-101 enrollment abroad, with 41 lung cancer patients treated - Stock Titan

Why Gold Prices Are CrashingACT NOW! Vincenzo Italiano (pm3QIbzhx7) - Fathom Journal

MAIA Biotechnology completes international enro... - Pluang

MAIA Biotechnology (MAIA) Edges Higher Amid Biotech Sector Interest — Key Levels in FocusCTA Positioning - dars.gov.et

Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo

MAIA Should I Buy - Intellectia AI

MAIA Gains on Setting up New Site - Baystreet.ca

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion - GlobeNewswire

MAIA Biotechnology opens patient enrollment at ... - Pluang

MAIA Biotechnology Surges 4.6%, Approaches Key Resistance at $1.43MESA MA - newsline.com

MAIA Biotechnology Holds Steady at $1.30, Consolidating Between Support and ResistanceETF Creation Redemption - newsline.com

MAIA Biotechnology (MAIA) Holds Steady at $1.30 as Consolidation Phase EmergesStock News - newsline.com

MAIA Biotechnology Q1 2026 Earnings: Narrower Loss and Pipeline Progress Signal Operational DisciplineDividend Increase Stocks - dars.gov.et

MAIA Biotechnology Activates Second US Site for Phase 2 Trial of Lung Cancer Treatment - Moomoo

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - The Manila Times

MAIA Biotechnology Activates and Opens Enrollment at Second - GlobeNewswire

MAIA Biotechnology Inc (MAIA) 財務データ

収益

当期純利益

現金流量

EPS

MAIAに似た銘柄